Viewing these files requires the Adobe Acrobat Reader®

Cardiovascular | Skeletal | Smooth

Cardiovascular

Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Ecandon RD, Elliott L, Bee R, Habiibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA. Dose-dependent Augmentation of Cardiac Systolic Funciton with the Selective Cardiac Myosin Activator, Omecamtiv Mecarbil: a First-in-man Study. The Lancet, 2011;378:667-75. Article

Cleland JGF, Teerlink JR, Senior R, Nifontov EM, McMurray JJV, Lang C, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzbert M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI. The Effects of the Cardiac Myosin Activator, Omecamtiv Mecarbil, on Cardiac Function in Systolic Heart Failure: a Double-blind, Placebo-controlled, Crossover, Dose-ranging Phase 2 Trial. The Lancet, 2011;378:676-83. Article

Malik FI, Morgan BP. Cardiac Myosin Activation Part 1: From Concept to Clinic. Journal of Molecular and Cellular Cardiology, 2011 October;51(4):454-461.

Malik FI, et al. Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure. Science, 2011 March;331;1439-1443. Article

Habibzadeh MR, Schiller NB, Malik FI, Chen MM, Saikali KG, Wolff AA, Goldman JH, Teerlink JR. Effect of the Selective Cardiac Myosin Activator, Omecamtiv Mecarbil, on Left Atrial Performance in Healthy Men. 2010 Heart Failure Society of America Annual Meeting (HFSA). San Diego, CA. September 2010. Poster presentation

Morgan BP, et al. Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac Myosin. ACS Medicinal Chemistry Letters, August 2010. Article

Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF. Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs with Systolic Heart Failure. Circulation Heart Failure, 2010 Jul;3(4):522-7. Epub 2010 May 24. Article

Greenberg BH, Chou W, Saikali KG, Escandon R, Lee JH, Chen MM, Malik F, Wolff AA, Shaburishvili T. Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina. 2009 Heart Failure Society of America Annual Meeting (HFSA), Boston, MA. September 2009. Poster presentation

Goldman JH, Teerlink JR, Saikali KG, Malik F, Wolff AA. Echocardiographic Detection of Increases in Ejection Fraction in Patients with Heart Failure Receiving the Selective Cardiac Myosin Activator, CK-1827452. 2009 Heart Failure Society of America Annual Meeting (HFSA), Boston, MA. September 2009. Poster presentation

Malik FI, Saikali KG, Chen MM, Lee JH, Goldman JH. An Analysis of the Response to CK-1827452, a Selective Cardiac Myosin Activator, in Stable Heart Failure Patients Stratified by Baseline Cardiac Function. 2009 Heart Failure Society of America Annual Meeting(HFSA), Boston, MA. September 2009. Poster presentation

Greenberg BH, Chou W, Saikali KG, Escandon R, Lee JH, Chen MM, Malik F, Wolff AA, Shaburishvili T. Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina. European Society of Cardiology (ESC) Congress 2009, Barcelona, Spain. August 2009. Poster presentation

Goldman JH, Teerlink JR, Saikali KG, Malik F, Wolff AA. Echocardiographic Detection of Increases in Ejection Fraction in Patients with Heart Failure Receiving the Selective Cardiac Myosin Activator, CK-1827452. European Society of Cardiology (ESC) Congress 2009, Barcelona, Spain. August 2009. Poster presentation

Goldman JH, Teerlink JR, Saikali KG, Malik F and Wolff AA. Echocardiographic Detection of Increases in Ejection Fraction in Patients with Heart Failure Receiving the Selective Cardiac Myosin Activator, CK-1827452. 2009 European Society of Cardiology, Heart Failure Congress, Nice, France. June 2009. Poster presentation

Greenberg BH, Chou W, Saikali KG, Escandon R, Lee JH, Chen MM, Malik F, Wolff AA, Shaburishvili T, and the CY 1221 Investigators. Phase II Safety Study Evaluating the Novel Cardiac Myosin Activator, CK-1827452, in Patients with Ischemic Cardiomyopathy and Angina. 2009 European Society of Cardiology, Heart Failure Congress, Nice, France. June 2009. Poster presentation

Senior R, Malik FI, Saikali KG, Lee JH, Chen MM, Brand G, Wolff AA, and the CY 1121 Investigators. The Selective Cardiac Myosin Activator, CK-1827452, Increases Systolic Function in a Concentration-Dependent Manner in Patients with Stable Heart Failure. 2009 Annual American College of Cardiology (ACC), Orlando, FL. March 2009. Poster presentation

Teerlink John R. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Failure Reviews, February 21, 2009. Article and Link to Website

Parker JD, Michaels AD, Kass DA, Wolff AA, Felker GM and Malik FI. Rationale and Design for a Phase II Study Evaluating the Effect of the Cardiac Myosin Activator, CK-1827452, on Cardiac Function, Hemodynamics, and Myocardial Oxygen Consumption in Patients with Heart Failure. 2008 Annual Heart Failure Society of America (HFSA) Conference. Toronto, Ontario, Canada. September 2008. Poster presentation

Cleland JGF, et al. First Clinical Trial of the Selective Cardiac Myosin Activator, CK-1827452, in Heart Failure: Effect of Dose and Plasma Concentration on Systolic Function. European Society of Cardiology (ESC) Congress 2008. August, 2008. Poster presentation

Shen Y, Zhang Y, Morgans DJ, Vatner SF, Malik F. A Novel Inotropic Agent That Activates Cardiac Myosin and Increases Cardiac Contractility Without Increasing MVO2 in Heart Failure with Left Ventricular Hypertrophy. American College of Cardiology Conference, Chicago, IL. March, 2008. Poster presentation

Anderson RL, Pokrovskii M, Suekawa K, Rodriguez HM, Elias, KA. The Cardiac Myosin Activator CK-1827452-Induced Myocyte Contractility is Unchanged in the Presence of β-Blockade. 2007 American Society of Cell Biology (ASCB) Conference, Washington, DC. December, 2007. Poster presentation

Jerling M, Chew T, Escandon R, Lee J, Saikali K, Venables E, Clarke C, Malik F, Wolff A. Oral Bioavailability of the Selective Cardiac Myosin Activator CK-1827452: Chronic Oral Inotropic Therapy for Heart Failure. 2007 Annual Heart Failure Society of America Meeting, Washington, DC. September, 2007. Poster presentation

Malik FI, Saikali KG, Clarke CP, Teerlink JR, Wolff AA. Systolic Ejection Time is a Sensitive Indicator of Left Ventricular Systolic Function During Treatment with the Selective Cardiac Myosin Activator, CK-1827452. 2007 Annual Heart Failure Society of America Meeting, Washington, DC. September, 2007. Poster presentation

Anderson R, Pokrovskii M, Elias K. Effects of Cardiac Myosin Activators on Excitation-Contraction (E-C) Coupling in Ventricular Myocytes. Biophysical Society 51st Annual Meeting, Baltimore, MD. March, 2007. Poster presentation

Rodriguez H, Kawas R, Malik F, Sakowicz R, Hartman J. The Cardiac Myosin Activator, CK-1827452, Accelerates the Enzymatic Step Gating Entry of Myosin into its Force Generating State. Biophysical Society 51st Annual Meeting, Baltimore, MD. March, 2007. Poster presentation

Anderson RL, Pokrovskii M, Elias KA. Effects of the Cardiac Myosin Activator CK-1316719 on Excitation-Contraction (E-C) Coupling in Ventricular Myocytes. 46th Annual American Society for Cell Biology Meeting, San Diego, CA. December, 2006. Poster presentation

Baliga R, Rodriguez HM, Guo D, Hartman JJ, Pierce DW, Sakowicz R, Morgan BP, Malik F, Finer JT. A Sensitive Assay for the Basal ATPase Activity of Cardiac Myosin. Society of Biomolecular Sciences Annual Meeting, Seattle (September 2006). Poster presentation

Anderson RL, Kawas RF, Pokrovskii MV, Godinez G, Lee KH, Mak J, Hartman JJ, Morgan BP, Morgans Jr., DJ, Malik F, Sakowicz R, Elias KA. Cardiac Myosin Activator CK-1316719 Increases Myofibril ATPase Activity and Myocyte Contractility in a Rat Model of Heart Failure. Heart Failure Society of America (HFSA), September, 2006. Poster presentation

Shen YT, Vatner SF, Morgans DJ, Malik F. Activating Cardiac Myosin, a Novel Inotropic Mechanism to Improve Cardiac Function in Conscious Dogs with Congestive Heart Failure. Heart Failure Society of America (HFSA), September, 2006. Poster presentation

Anderson RL, Sueoka SH, Lee KH, Rodriguez HM, Kawas R, Godinez G, Morgan BP, Sakowicz R, Morgans Jr, DJ, Malik F, Elias KA. In Vitro and In Vivo Characterization CK-1827452, a Selective Cardiac Myosin Activator. Heart Failure Society of America (HFSA), September, 2006. Poster presentation

Rodriguez HM, Sylvester S, Kawas R, Malik F, Sakowicz R. Activation of the Cardiac Sarcomere by a Small Molecule Agent, CK-1213296. Biophysical Society Annual Meeting. February, 2006. Poster presentation

Rodriguez HM, Sylvester S, Hartman J, Shen YT, Kass DA, Vatner SF, Malik F, Sakowicz R. A Detailed Kinetic Analysis of the Cardiac Myosin Activator, CK-1213296, Suggests It Improves Cardiac Contractility by Accelerating Transition from the Weak to Strongly Bound States. Molecular Mechanisms of Cardiac Disease and Regeneration. February, 2006. Poster presentation

Lenzi D, Fritsch A, Alexander G, Hansen R, Cong G, Zink W, Godinez G, Pham A, Trautman J, Pierce DW, Malik F, Finer JT. A Multiplexed and Automated Imaging Assay of Cardiac Myocyte Contractility. American Society of Cell Biology (ASCB) December, 2005. Poster presentation

Anderson RL, Sueoka SH, Rodriguez HM, Lee KH, Cox DR, Kawas R, Morgan BP, Sakowicz R, Morgans Jr DJ, Malik F, Elias KA. In Vitro and In Vivo Efficacy of the Cardiac Myosin Activator CK-1827452. American Society of Cell Biology (ASCB) December, 2005. Poster presentation

Malik F, Elias KA, Finer JT, Morgan BP, Sakowicz R, Anderson R, Baliga R, Conn L, Cox D, Garard M, Hartman J, Irvine J, Kawas R, Kraynack E, Kuklov A, Lee KH, Lu P, Muci A, Pierce DW, Rodriguez H, Suehiro I, Sueoka SH, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, and Morgans DJ . Direct Activation of Cardiac Myosin by CK-1827452 Improves Cardiac Function in a Dog Heart Failure Model. Heart Failure Society of America Meeting, September 2005. Poster presentation

Malik F, Shen Y, Katori T, Sueoka SH, Anderson R, Cox D, Garard M, Hartman J, Kim S, Kraynack E, Kuklov A, Lee KH, Lu P, Muci A, Niu C, Rodriguez H, Suehiro I, Sylvester S, Tochimoto T, Elias KA, Morgan BP, Sakowicz R, Kass DA, Vatner SF, Morgans DJ. Direct Activation of Cardiac Myosin, A Novel Mechanism for Improving Cardiac Function. American Heart Association (AHA) Keystone, July 2005. Poster presentation

Anderson R, Niu C, Elias K. The Cardiac Myosin Activator, CK-1122534, Overcomes the Myosin II Inhibitors 2, 3-Butanedione-2-Monoxime and (-)-S-Blebbistatin without Affecting the Ca²⁺ Transient in Ventricular Myocytes. American Society of Cell Biology, December 2004. Poster presentation

Niu C, Anderson R, Cox D, Qian X, Morgan B, Malik F, Morgans Jr D, Elias K. The Cardiac Myosin Activator, CK-1122534, Increases Contractility in Adult Cardiac Myocytes without Altering the Calcium Transient. American Society of Cell Biology, December 2004. Poster presentation

Niu C, Cox D, Lee K, Sylvester S, Sueoka S, Qian X, Feng B, Malik F, Morgans Jr D, Hartman J, Sakowicz R, Elias K. Cellular Responses of the Myosin Activator CK-0689705 in Normal and Heart Failure Models. American Society of Cell Biology, December 2004. Poster presentation

Rodriguez H, Sylvester S, Qian X, Morgan B, Morgans Jr D, Malik F, Sakowicz R. Activation of Cardiac Sarcomere ATPase by CK-1122534, a Small Molecule Agent that Specifically Targets Cardiac Myosin. American Society of Cell Biology, December 2004. Poster presentation

Rodriguez H, Sylvester S, Sakowicz R. Interaction of Myosin with Blebbistatin Reported by Fluorescence Spectroscopy. American Society of Cell Biology, December 2004. Poster presentation

Niu C, Anderson RL, Cox DR, Morgan BP, Morgans Jr DJ, Malik F, Elias KA. The Cardiac Myosin Activator, CK1122534, Increases Contractility in Adult Cardiac Myocytes But Does Not Affect the Transient or Depend on Second Messenger Signaling. American Heart Association, November 2004. Poster presentation

Skeletal

Cedarbaum JM, Mitsumoto H, Pestronk A, Ringel S, Florence J, Sanjak M, Brooks BR. The ALSFRS @ 20: Evolution of the ALSFRS-R History, Clinimetric Properties and Future Directions. 22nd International Symposium on ALS/MND, Sydney, Australia, November 2011. Poster presentation

Shefner J, Brooks BR, Simmons Z, Mitsumoto H, Wolff AA, Lee JH, Jones DS, Mao J, Meng L, Cedarbaum JM, The CY 4024 Investigator Group. A Study to Evaluate Safety, Tolerability and Clinical Outcomes Following Repeated Doses of CK-2017357 (CK-357) in Patients with Amyotrophic Lateral Sclerosis. 22nd International Symposium on ALS/MND, Sydney, Australia, November 2011. Poster presentation

Hiatt WR, Hirsch AT, Bauer TA, Malik F, Lee J, Lin Y, Han FX, Chen MM, Jones D, Cedarbaum JM, Wolff AA. Efficacy and Tolerability of the Novel Fast Skeletal Muscle Troponin Activator, CK-2017357, in Patients with Claudication. 22nd Annual Sessions of the Society for Vascular Medicine. Boston, MA, June 2011 Poster presentation

Bauer TA, Hirsch AT, Malik F, Wolff AA, Hiatt WR. Bilateral Concentric Heel Raise Test: A Novel Functional Endpoint for Early Stage Clinical Trials in Peripheral Artery Disease (PAD). Boston, MA, June 2011 Poster presentation

Hinken A, Driscoll L, Godinez G, Lee K, Pannirselvan M, Hartman JJ, Muci AR, Morgans DJ, Morgan BP, Russell AJ, Jasper J, Malik FA. A novel Fast Skeletal Muscle Activator, CK-2017357, Improves Muscle Function in a Rodent Model of Myasthenia Gravis. 2011 Experimental Biology Conference, Washington, DC. April 2011. Poster presentation

Hansen R, Saikali KG, Chou W, Russell A, Chen M, Vijayakumar V, Stoltz R, Baudry S, Enoka R, Morgans D, Wolff AA, Malik F. CK-2017357, a Novel Activator of Fast Skeletal Muscle, Increases Isometric Force Evoked by Electrical Stimulation of the Anterior Tibialis Muscle in Healthy Male Subjects. Society for Neuroscience 40th Annual Meeting: Neuroscience 2010. November 2010. Poster presentation

Mao J, Vo CH, Xu D, Bergnes G, Morgan BP, Morgans DJ. Cross-Species Pharmacokinetics of CK-2017357, a Novel Activator of the Fast Skeletal Sarcomere. 2010 FIP PSWC/AAPS Annual Meeting and Exposition. New Orleans, LA. November 2010. Poster presentation

Aaron C Hinken, Lena Driscoll, Ken Lee, Jim J Hartman, David Marquez, Richard Hansen, Alex Muci, Bradley Morgan, David J Morgans Jr, Alan J Russell, Fady Malik. The Fast Skeletal Troponin Activator, CK-2017357, Reduces Muscle Fatigue in an in situ Model of Vascular Insufficiency. 2010 Annual Aging Muscle Symposium, San Francisco, California. September 2010. Poster presentation

Mao J, Chou W, Malik F, Lee J, Gabus C, Seroogy J, Saikali K, Morgans D, Wolff A. Oral Pharmacokinetics of CK-2017357 in Healthy Subjects. 39th Annual Meeting of the College of Clinical Pharmacology (ACCP.) Baltimore, MD. September 2010. Poster presentation

Chou W, Hansen R, Saikali KG, Russell A, Chen MM, Vijayakumar V, Stoltz R, Baudry S, Enoka R, Morgans D, Wolff AA, Malik F. CK-2017357, a Novel Activator of Fast Skeletal Muscle, Increases Isometric Force Evoked by Electrical Stimulation of the Anterior Tibialis Muscle in Healthy Male Subjects. XII International Congress on Neuromuscular Diseases, Naples, Italy. July 2010. Poster presentation

Aaron C Hinken, Lena Driscoll, Ken Lee, Jim J Hartman, David Marquez, Richard Hansen, Alex Muci, Bradley Morgan, David J Morgans Jr, Alan J Russell, Fady Malik. The Fast Skeletal Troponin Activator, CK-2017357, Reduces Muscle Fatigue in an in situ Model of Vascular Insufficiency. Society for Vascular Medicine’s 2010 Annual Meeting: 21st Annual Scientific Sessions, Cleveland, OH. April 2010. Poster presentation

Aaron C Hinken, Lena C Driscoll, Ken Lee, Jim J Hartman, David Marquez, Richard Hansen, Alex Muci, Bradley Morgan, Fady Malik, Alan J Russell. Fast Skeletal Troponin Activator, CK-1909178, Reduces Muscle Fatigue in a Model of Peripheral Artery Disease in situ. Biophysical Society 54th Annual Meeting,San Francisco, CA. February 2010. Poster presentation

Raja Kawas, Alan Russell, Alex Muci, Bradley Morgan, Fady Malik, Jim Hartman. The Small Molecule Skeletal Sarcomere Activator, CK-2017357, is a Calcium Sensitizer that Binds Selectively to the Fast Skeletal Troponin Complex. Biophysical Society 54th Annual Meeting, San Francisco, CA. February 2010. Poster presentation

Russell AJ, Lee K, Hartman JJ, Marquez D, Hansen R, Muci A, Morgan B, Jia Z, Morgans DJ, Malik F. The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force and Reduces Muscle Fatigue in vitro and in situ. 5th Cachexia Conference, Barcelona, Spain. December 2009. Poster presentation

Russell AJ, Lee K, Jia Z, Muci A, Browne W, Tomlinson M, Hartman JJ, Hansen R, Hinken AC, Albertus D, Claflin D, Morgans DJ., Morgan B, Malik F. The Fast Skeletal Troponin Activator, CK-2017357, Increases Skeletal Muscle Force in vitro and in situ. 2009 Experimental Biology Conference, New Orleans, LA. April 2009. Poster presentation

Lee K, Hartman J, Hansen R, Clarke D, Hinken A, Muci A, Morgan B, Vijayakumar V, Jia Z, Malik F, Russell A. The Fast Skeletal Troponin Activator, CK-1909178, Increases Skeletal Muscle Force in-vitro and in-situ. Biophysical Society 53rd Annual Meeting, Boston, MA. March 2009. Poster presentation

Kawas R, Russell A, Rodriguez H, Suekawa K, Muci A, Morgan B, Malik F, Hartman J. The Small Molecule Skeletal Sarcomere Activator, CK-1909178, is a Calcium Sensitizer that Binds Selectively to the Fast Skeletal Troponin Complex. Biophysical Society 53rd Annual Meeting. Boston, MA. March 2009. Poster presentation

Marquez D, Tomlinson M, Lievers J, Hartman J, Russell A, Hansen R. An Automated Apparatus for Isometric Force Analysis of Skinned Muscle Fibers. Biophysical Society 53rd Annual Meeting. Boston, MA. March 2009. Poster presentation

Smooth

Pannirselvam M, Jia Z, Durham N, Godinez G, Zavodovskaya M, Lenzi D, Clancy S, Hartman JJ, Morgans DJ, Morgan BP, Qian X, Malik FI. The Direct Smooth Muscle Myosin Inhibitor, CK-2125927, Represents a Novel Therapeutic Mechanism of Bronchodilation. 2011 Experimental Biology Conference, Washington, DC. April 2011. Poster presentation

Zhiheng Jia, Guillermo Godinez, Nickie Durham, Xi Wang, Chihyuan Chuang, Pu-Ping Lu, Wenyue Wang, Bing Yao, Jeffrey Warrington, Sheila Clancy, James J Hartman, David J Morgans Jr, Bradley P Morgan, Xiangping Qian, Fady I Malik, Malar Pannirselvam. The Direct Smooth Muscle Myosin Inhibitor, CK-2018571, Represents a Novel Therapeutic Mechanism for Bronchodilation. American Thoracic Society's 2010 International Conference, May 2010, New Orleans, LA. Poster presentation

Sheila Clancy, Zhiheng Jia , Malar Pannirselvam, Xiangping Qian, Bradley Morgan, Fady Malik, Jim Hartman. The Small Molecule Smooth Muscle Myosin Inhibitor, CK-2018571, Selectively Inhibits ATP Hydrolysis and Relaxes Smooth Muscle in vitro. Biophysical Society 54th Annual Meeting,San Francisco, CA. February 2010. Poster presentation

David Ho, Xin Zhao, Li Chen, You-Tang Shen, Xiangping Qian, David J. Morgans, Stephen F. Vatner, Fady I. Malik. Inhibition of Smooth Muscle Myosin, a Novel Therapeutic Approach for Pulmonary Hypertension. American Heart Association (AHA) 2009 Scientific Sessions. Orlando, FL. November 2009. Poster presentation

Qian X, Wang X, Hartman JJ, Jia Z, Clancy S, Yao B, Chuang C, Lu P, Pannirselvam M, Morgans DJ, Morgan BP, Malik FI. A Direct Inhibitor of Smooth Muscle Myosin as a Novel Therapeutic Approach for the Treatment of Systemic Hypertension. American Society of Hypertension 24th Annual Scientific Meeting and Exposition. San Francisco, CA. May 2009. Poster presentation